Efficacy And Safety Of The Oral PCSK9 Inhibitor, MK-0616, A Macrocyclic Peptide, In The Treatment Of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

Published: March 10, 2023, 8:46 p.m.

Efficacy And Safety Of The Oral PCSK9 Inhibitor, MK-0616, A Macrocyclic Peptide, In The Treatment Of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial